Insider Trading Alert - IPXL, ITMN And GMCR Traded By Insiders
at The Street - Tue May 13, 11:30AM CDT
Stocks with insider trader activity include IPXL, ITMN and GMCR
Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago InterMune Is Up 12.2% (ITMN)
Comtex SmarTrend(R) - Mon May 12, 11:34AM CDT
11 days ago, on May 1st, 2014, InterMune (NASDAQ:ITMN) reported its earnings. Analysts, on average, expected a loss of $0.62 per share on sales of $28.4 million. InterMune actually reported a loss of $0.59 per share on sales of $30.3 million, beating EPS estimates by $0.03 and beating revenue estimates by $1.9 million. Shares of InterMune have climbed from $32.16 to $36.07, representing a gain of 12.2% since the company reported earnings 11 days ago.
InterMune Announces Upcoming Data Presentations at 2014 American Thoracic Society Meeting
PR Newswire - Mon May 12, 7:00AM CDT
InterMune, Inc. (NASDAQ: ITMN) today announced that several investigational molecules and data from studies of pirfenidone will be presented at the 2014 International Conference of the American Thoracic Society (ATS), May 16 - 21, in San Diego, Calif. in a total of 18 abstracts. Updates on InterMune's small molecule fibrosis research programs, including pirfenidone analogs and inhibitors of LPA1 and LOXL2, will be presented at the meeting. Additionally, data will be presented from studies of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), including the primary efficacy and safety analyses of the Phase 3 ASCEND trial, as well as other data that further characterize the safety profile of pirfenidone.
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun May 11, 11:00AM CDT
It was a rocky week on Wall Street, with Nasdaq stocks inching lower and the Dow inching higher, but there were plenty of stocks really making some serious moves. Let's take a closer look at five of this past week's biggest scorchers. ...
This Relative Strength Play Is Ready to Pop
at The Street - Tue May 06, 1:07PM CDT
InterMune is telling a fundamentally and technically bullish story.
Use Options For A Chance To Buy ITMN At A 33% Discount
at The Street - Tue May 06, 10:49AM CDT
Looking back to 54 days ago, InterMune Inc. priced a 7,500,000 share secondary stock offering at $32.75 per share.
Why King Digital Entertainment, Intermune, and Pharmacyclics Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon May 05, 7:05PM CDT
This morning, it looked as though Monday would be a horrible day for the stock market, as worries about the health of China's economic growth and ongoing turmoil in Ukraine combined to send stocks falling at the open. Slowly but surely, though,...
After Yesterday's Rally of 7.07% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 05, 5:00PM CDT
InterMune (NASDAQ:ITMN) traded in a range yesterday that spanned from a low of $32.29 to a high of $35.51. Yesterday, the shares gained 7.1%, which took the trading range above the 3-day high of $33.88 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Intermune (ITMN) Stock Is Up Today
at The Street - Mon May 05, 12:38PM CDT
Intermune (ITMN) continues the momentum it gained from the release of its first quarter earnings results late last week as the biotech's stock is up 5.9% in trading today.
InterMune Up on Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 10:00AM CDT
InterMune's (ITMN) first-quarter 2014 adjusted loss per share of 60 cents was narrower than the Zacks Consensus Estimate of a loss of 62 cents.
Despite Esbriet Sales Nearly Tripling, InterMune's Loss Widens by 7%
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 6:49PM CDT
Momentum is building for biopharmaceutical mid-cap InterMune , which reported strong year-over-year sales gains in the first quarter for lead drug Esbriet, a treatment for idiopathic pulmonary fibrosis. For the quarter, InterMune reported a...
InterMune Reports First Quarter 2014 Financial Results, Clinical Development and Business Highlights
PR Newswire - Thu May 01, 3:01PM CDT
InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the first quarter ended March 31, 2014. The company also highlighted recent clinical development and business highlights, and raised its forward-looking revenue guidance for 2014.
Today's Biotech Stocks to Watch: BioMarin Pharmaceutical Inc, InterMune, Inc. and Seattle Genetics I
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:30AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for BioMarin , InterMune , and Seattle Genetics . BioMarin will hold an earnings call after the bell today Orphan drug specialist BioMarin will report...
Watch for InterMune to Potentially Pullback After Gaining 3.17% Yesterday
Comtex SmarTrend(R) - Tue Apr 29, 5:48PM CDT
InterMune (NASDAQ:ITMN) traded in a range yesterday that spanned from a low of $30.20 to a high of $32.07. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $30.73 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
InterMune To Release First Quarter Financial Results On May 1
PR Newswire - Wed Apr 23, 7:00AM CDT
InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its first quarter 2014 financial results at the close of the U.S. markets on Thursday, May 1, 2014. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.
After Yesterday's Decline of 1.55%, InterMune Offers Investors Better Value
Comtex SmarTrend(R) - Tue Apr 15, 5:23PM CDT
InterMune (NASDAQ:ITMN) traded in a range yesterday that spanned from a low of $24.27 to a high of $28.18. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $26.26 on volume of 4.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Shares of ITMN Up 98.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 15, 9:07AM CDT
SmarTrend identified an Uptrend for InterMune (NASDAQ:ITMN) on February 12th, 2014 at $13.97. In approximately 2 months, InterMune has returned 98.78% as of today's recent price of $27.77.
Biotech Tweet of the Week: Love Being Private
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:57PM CDT
This week's tweet of the week comes from Luke Timmerman, with a quote from Moderna Therapeutics' President and CEO Stephane Bancel, who says he loves being a private company because he has more control over what information gets released. Public...
Insider Trading Alert - ITMN, DXCM And MU Traded By Insiders
at The Street - Fri Apr 04, 10:30AM CDT
Stocks with insider trader activity include ITMN, DXCM and MU
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.